Dexibuprofen

Dexibuprofen

SCHEMBL43531

CC(C)Cc1ccc([C@H](C)C(=O)O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1PTGS2

The experimentally established mechanism targets of Dexibuprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 known ✓ P23219 5/20 1.00
PTGS2 known ✓ P35354 5/20 1.00
CXCR1 P25024 5/20 1.00
CXCR2 P25025 5/20 1.00
LMNA P02545 2/20 1.00
CYP2C9 P11712 2/20 1.00
AKR1C3 P42330 2/20 1.00
ALB P02768 1/20 1.00
ESR1 P03372 1/20 1.00
ALOX5 P09917 1/20 1.00
RARB P10826 1/20 1.00
ADRB3 P13945 1/20 1.00
NFKB1 P19838 1/20 1.00
HTR2A P28223 1/20 1.00
NR1I3 Q14994 1/20 1.00
SLC22A6 Q4U2R8 1/20 1.00
CXCL8 P10145 1/20 1.00
TSHR P16473 1/20 1.00
AKR1C2 P52895 1/20 1.00
BLM P54132 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ibuprofen SCHEMBL1651685 1.00 PTGS1 (1.00) PTGS1PTGS2CXCR1CXCR2LMNA
Ibuprofen SCHEMBL19439559 1.00 PTGS1 (1.00) PTGS1PTGS2CXCR1CXCR2LMNA
Ibuprofen SCHEMBL7037276 1.00 PTGS1 (1.00) PTGS1PTGS2CXCR1CXCR2LMNA
Dexibuprofen SCHEMBL30091137 1.00 PTGS1 (1.00) PTGS1PTGS2CXCR1CXCR2LMNA
Ibuprofen SCHEMBL3001 1.00 PTGS1 (1.00) PTGS1PTGS2CXCR1CXCR2LMNA
Ibuprofen SCHEMBL239446 1.00 PTGS1 (1.00) PTGS1PTGS2CXCR1CXCR2LMNA
(R)-Ibuprophen SCHEMBL29057 1.00 PTGS1 (1.00) PTGS1PTGS2CXCR1CXCR2LMNA
Ibuprofen SCHEMBL19439560 1.00 PTGS1 (1.00) PTGS1PTGS2CXCR1CXCR2LMNA
Ibuprofen SCHEMBL8754799 1.00 PTGS1 (1.00) PTGS1PTGS2CXCR1CXCR2LMNA
Ibuprofen SCHEMBL5971382 0.98 PTGS1 (0.96) PTGS1PTGS2CXCR1CXCR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 13209 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
US-12605432-B2 Combinations for antigen based therapy DIAMYD MEDICAL AB (SE) 2026-04-21 US claimed
US-12600696-B2 Aromatic compounds Xeniopro GmbH (DE) 2026-04-14 US claimed
US-20260097023-A1 UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND FAMOTIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN AND/OR UPSET STOMACH SCHABAR RES ASSOCIATES LLC (US) 2026-04-09 US claimed
US-20260069532-A1 METHOD FOR MORSELIZING AND/OR TARGETING PHARMACEUTICALLY ACTIVE PRINCIPLES TO SYNOVIAL TISSUE MEDINCELL S.A. (FR) 2026-03-12 US claimed
US-12569451-B2 Bio-inspired tissue-adhesive hydrogel patch and uses thereof Cellartgen Inc. (KR) 2026-03-10 US claimed
US-12558309-B2 Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue MEDINCELL S.A. (FR) 2026-02-24 US claimed
US-20260041660-A1 Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms CHANG RICHARD L (US) 2026-02-12 US claimed
US-12514846-B2 Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach SCHABAR RESEARCH ASSOCIATES LLC (US) 2026-01-06 US claimed
EP-0459695-B1 Taste masking and sustained release coatings for pharmaceuticals MCNEIL PPC INC (US) 1995-03-15 EP claimed
EP-0602112-A1 HIGH CONTENT IBUPROFEN AGGLOMERATES AND PROCESS TO PREPARE THEM The Boots Company PLC (GB) 1994-06-22 EP claimed
US-5240712-A Solid sustained release unit dosage forms of 2-(4-isobutylphenyl)propionic acid THE BOOTS COMPANY PLC (GB) 1993-08-31 US claimed
WO-1993004676-A1 HIGH CONTENT IBUPROFEN AGGLOMERATES AND PROCESS TO PREPARE THEM THE BOOTS COMPANY PLC (GB) 1993-03-18 WO claimed
US-4701470-A Treatment of Type II Herpes virus with ibuprofen THE UPJOHN COMPANY (US) 1987-10-20 US claimed
US-4447451-A ADMINISTERING IBUPROFEN THE UPJOHN MANUFACTURING COMPANY M (US) 1984-05-08 US claimed
US-4439450-A Treatment of the blood-brain barrier with ibuprofen THE UPJOHN MANUFACTURING COMPANY M (US) 1984-03-27 US claimed
EP-0070714-A1 Use of ibuprofen or flurbiprofen for the manufacture of a medicament for treating respiratory disorders THE UPJOHN COMPANY (US) 1983-01-26 EP claimed
US-4346108-A Method for preventing adhesion formation THE UPJOHN MANUFACTURING COMPANY M (US) 1982-08-24 US claimed
US-4154962-A Synthesis of hydratropic acid and some of its alkyl derivatives AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 1979-05-15 US claimed